{
    "medicine_id": "7c5b1c18f5ca8967fdda15f491c8e8e8dfbdaf5b",
    "platform_id": "DB09028",
    "metadata": {
        "name": "Harvoni 90 mg Tablet film coated",
        "composition": "90 mg Cytisine",
        "clinical_particulars": {
            "therapeutic_indications": "Indicated for use in smoking cessation",
            "contraindications": {
                "disease": "The therapeutic index of cytisine is wide Large doses can interfere with breathing and cause death From MSDS orl mus LD50 101 mg kg ipr mus LD50 8550 ug kg ivn mus LD50 1730 ug kg scu rat LD50 8750 ug kg",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Various models have been run where the affinity of nAChR agonists to the receptor subtype are tested to help identify the molecules groups and steric conformation that are vital to greater affinity By using a nAChR muscle receptor subtype \u03b11 2\u03b21\u03b4\u03b3 model the following results were obtained anatoxin epibatidine acetylcholine DMPP CYTISINE pyrantel nicotine coniine tubocurare lobeline where anatoxin had the highest activity efficacy and tubocurare the lowest Acetylcholine on the other hand induced a much longer opening time of the receptor though anatoxin is more potent The results suggest that anatoxin derivatives would be helpful in understanding structure activity relationships SAR for muscle nAChRs Cooper et al 1996",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}